These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

862 related items for PubMed ID: 15725968

  • 1. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [Abstract] [Full Text] [Related]

  • 2. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ.
    Neurology; 2005 Dec 27; 65(12):1941-9. PubMed ID: 16380617
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Family functioning and psychosocial characteristics in children with attention deficit hyperactivity disorder with comorbid oppositional defiant disorder or conduct disorder].
    Kiliç BG, Sener S.
    Turk Psikiyatri Derg; 2005 Dec 27; 16(1):21-8. PubMed ID: 15793695
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan 27; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 12. Neurocognitive function in attention-deficit-hyperactivity disorder with and without comorbid disruptive behaviour disorders.
    Barnett R, Maruff P, Vance A.
    Aust N Z J Psychiatry; 2009 Aug 27; 43(8):722-30. PubMed ID: 19629793
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    Atomoxetine ADHD and Comorbid MDD Study GroupLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. bangsme@lilly.com, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR.
    J Child Adolesc Psychopharmacol; 2007 Aug 27; 17(4):407-20. PubMed ID: 17822337
    [Abstract] [Full Text] [Related]

  • 14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 27; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):145-54. PubMed ID: 18403134
    [Abstract] [Full Text] [Related]

  • 17. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder.
    Gau SS, Ni HC, Shang CY, Soong WT, Wu YY, Lin LY, Chiu YN.
    Aust N Z J Psychiatry; 2010 Feb 01; 44(2):135-43. PubMed ID: 20113302
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 20. ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders?
    Connor DF, Doerfler LA.
    J Atten Disord; 2008 Sep 01; 12(2):126-34. PubMed ID: 17934178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.